Oricell Therapeutics
Shanghai, CN · 24 employees on LinkedIn · 3 known investors
Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer. Based in Shanghai, it builds proprietary antibody and CAR platforms (OriAb, OriCAR) to create cancer immunotherapies for unmet oncology needs such as liver, gastric, pancreatic, biliary, and ovarian cancers.
Founders & leadership
HY
Helen YanginCo-founder/Chairwoman/CEO
Investors · 3
Funding
SEC filings, press & company announcements$110M disclosed across 1 round · 2026
- $110MraisedApr 2026 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Oricell Therapeutics do?
- Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer. Based in Shanghai, it builds proprietary antibody and CAR platforms (OriAb, OriCAR) to create cancer immunotherapies for unmet oncology needs such as liver, gastric, pancreatic, biliary, and ovarian cancers.
- Who founded Oricell Therapeutics?
- Oricell Therapeutics was founded by Helen Yang.
- Who are Oricell Therapeutics's investors?
- Oricell Therapeutics's investors include Qiming Venture Partners, Vivo Capital, Quan Capital.
- How much funding has Oricell Therapeutics raised?
- Oricell Therapeutics has disclosed $110M raised across 1 round.
- Where is Oricell Therapeutics headquartered?
- Oricell Therapeutics is headquartered in Shanghai, CN.